La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Navamedic Crescita futura

Future criteri di controllo 4/6

Navamedic prevede che gli utili e i ricavi cresceranno rispettivamente di 26.5% e 12.5% all'anno. Si prevede che l'EPS crescerà di 26.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.5% in 3 anni.

Informazioni chiave

26.9%

Tasso di crescita degli utili

27.3%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	15.2%
Tasso di crescita dei ricavi	12.3%
Rendimento futuro del capitale proprio	19.5%
Copertura analitica	Low
Ultimo aggiornamento	23 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

Previsioni di crescita degli utili e dei ricavi

OB:NAVA - Stime future degli analisti e dati finanziari passati (NOK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	765	64	40	51	1
12/31/2025	652	54	17	27	2
12/31/2024	567	32	39	44	1
6/30/2024	543	25	3	6	N/A
3/31/2024	511	-11	-9	-6	N/A
12/31/2023	512	3	0	2	N/A
9/30/2023	503	24	47	47	N/A
6/30/2023	454	20	31	33	N/A
3/31/2023	441	43	37	40	N/A
12/31/2022	382	29	16	18	N/A
9/30/2022	356	12	7	9	N/A
6/30/2022	327	8	2	2	N/A
3/31/2022	283	4	-8	-7	N/A
12/31/2021	278	1	-2	-1	N/A
9/30/2021	244	-7	1	2	N/A
6/30/2021	237	-6	-1	2	N/A
3/31/2021	213	-8	-4	0	N/A
12/31/2020	210	-16	-8	-3	N/A
9/30/2020	202	-22	-20	-16	N/A
6/30/2020	194	-24	-18	-15	N/A
3/31/2020	199	-26	-13	-12	N/A
12/31/2019	189	-16	12	13	N/A
9/30/2019	193	-1	1	4	N/A
6/30/2019	189	0	5	5	N/A
3/31/2019	187	10	-1	-1	N/A
12/31/2018	184	4	-38	-38	N/A
9/30/2018	177	-20	-26	-20	N/A
6/30/2018	178	-13	-17	-11	N/A
3/31/2018	222	-20	N/A	41	N/A
12/31/2017	258	-16	N/A	59	N/A
9/30/2017	294	3	N/A	43	N/A
6/30/2017	315	4	N/A	29	N/A
3/31/2017	292	-9	N/A	-13	N/A
12/31/2016	274	-11	N/A	-15	N/A
9/30/2016	258	-28	N/A	-8	N/A
6/30/2016	254	-30	N/A	-7	N/A
3/31/2016	247	-17	N/A	10	N/A
12/31/2015	248	-11	N/A	23	N/A
9/30/2015	245	-4	N/A	24	N/A
6/30/2015	242	1	N/A	8	N/A
3/31/2015	242	1	N/A	-9	N/A
12/31/2014	223	-1	N/A	-11	N/A
9/30/2014	204	1	N/A	-12	N/A
6/30/2014	182	-2	N/A	-8	N/A
3/31/2014	161	-3	N/A	-16	N/A
12/31/2013	152	-1	N/A	-16	N/A
9/30/2013	134	0	N/A	-18	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di NAVA ( 26.5% all'anno) è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Si prevede che gli utili di NAVA ( 26.5% all'anno) cresceranno più rapidamente del mercato Norwegian ( 11.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di NAVA cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di NAVA ( 12.5% all'anno) crescerà più rapidamente del mercato Norwegian ( 2.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di NAVA ( 12.5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di NAVA sarà basso tra 3 anni ( 19.5 %).

Navamedic Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 12%

Price target decreased by 7.1% to kr45.50

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 53%

Recent updates

Consensus EPS estimates fall by 12%

Director recently bought kr1.5m worth of stock

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

Price target decreased by 7.1% to kr45.50

First quarter 2024 earnings released

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021

New 90-day low: kr17.45

New 90-day low: kr18.20

Chief Executive Officer exercised options to buy kr2.3m worth of stock.

New 90-day low: kr18.50

Earnings released

Previsioni di crescita degli utili e dei ricavi